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The aim of this blinded, randomised, prospective clinical trial was to determine whether the 27 
addition of magnesium sulphate to spinally-administered ropivacaine would improve peri-28 
operative analgesia without impairing motor function in dogs undergoing orthopaedic surgery. 29 
Twenty client-owned dogs undergoing tibial plateau levelling osteotomy were randomly 30 
assigned to one of two treatment groups: group C (control, receiving hyperbaric ropivacaine 31 
by the spinal route) or group M (magnesium, receiving a hyperbaric combination of magnesium 32 
sulphate and ropivacaine by the spinal route). During surgery, changes in physiological 33 
variables above baseline were used to evaluate nociception. Arterial blood was collected before 34 
and after spinal injection, at four time points, to monitor plasma magnesium concentrations. 35 
Post-operatively, pain was assessed with a modified Sammarco pain score, a Glasgow pain 36 
scale and a visual analogue scale, while motor function was evaluated with a modified Tarlov 37 
scale. Assessments were performed at recovery and 1, 2 and 3 h thereafter. Fentanyl and 38 
buprenorphine were administered as rescue analgesics in the intra- and post-operative periods, 39 
respectively. 40 
 41 
Plasma magnesium concentrations did not increase after spinal injection compared to baseline. 42 
Group M required less intra-operative fentanyl, had lower Glasgow pain scores and 43 
experienced analgesia of longer duration than group C (527.0 ± 341.0 min vs. 44 
176.0 ± 109.0 min). However, in group M the motor block was significantly longer, which 45 
limits the usefulness of magnesium for spinal analgesia at the investigated dose. Further 46 
research is needed to determine a clinically effective dose with shorter duration of motor block 47 
for magnesium used as an additive to spinal analgesic agents. 48 
 49 
Introduction 50 
Prevention and control of pain is one of the most important ethical obligations of veterinarians. 51 
As a result, various aspects of this fascinating branch of anaesthesia have been explored, and a 52 
number of novel techniques have been developed over the past decades to improve peri-53 
operative pain management. It is likely that a multimodal approach has increased efficacy and, 54 
consequently, there has been particular interest in agents that, although not classified as 55 
analgesics, do exert antinociceptive effects (KuKanich, 2013, Madden et al, 2014, Crociolli et 56 
al, 2015; Norkus et al., 2015). 57 
 58 
The use of magnesium has generated widespread interest as it could prevent central 59 
sensitisation by acting as a non-competitive antagonist at N-methyl-D-aspartate receptors in 60 
the dorsal horn, in a voltage-dependent fashion. Magnesium sulphate is commercially available 61 
in Europe, and the formulation developed for parenteral use is inexpensive, stable at room 62 
temperature and approved for use in dogs. Several studies in both human patients and dogs 63 
suggest that magnesium sulphate exerts antinociceptive effects (Bahrenberg et al., 2015), and 64 
consistently prolongs the duration of analgesia of various local anaesthetics and opioid 65 
combinations when administered via either the epidural or spinal route (Buvanendran et al, 66 
2002, Oezalevli et al, 2005, Arcioni et al, 2007). Additionally, a study in dogs investigating the 67 
neurotoxicity of intrathecal magnesium sulphate found that a dose rate of 3 mg/kg did not cause 68 
neurological deficits or histopathological changes in the spinal cord (Simpson et al., 1994). 69 
 70 
Overall, these findings supported our hypothesis that a clinical trial investigating the effects of 71 
spinally administered magnesium in client-owned dogs would be feasible and ethically 72 
acceptable. The aim of this study was to compare the intensity and duration of peri-operative 73 
analgesia and motor block in client-owned dogs undergoing elective orthopaedic surgery, after 74 
spinal administration of either ropivacaine, or a combination of ropivacaine–magnesium 75 
sulphate. Our hypothesis was that the inclusion of magnesium sulphate would provide longer 76 
lasting, better quality analgesia than ropivacaine alone, without impairing neurological 77 
function of the pelvic limbs and/or prolonging the duration of the motor block. 78 
 79 
Materials and methods 80 
 81 
Animals and determination of sample size 82 
Twenty client-owned dogs undergoing elective tibial plateau levelling osteotomy (TPLO) 83 
between May 2014 and March 2015 were enrolled in the study. On arrival, a pre-anaesthetic 84 
physical examination was performed, as well as venous blood sampling for haematology and 85 
chemistry. Exclusion criteria were an American Society of Anaesthesiologists risk category 86 
higher than 2, infectious skin diseases affecting the lumbosacral area, and bleeding disorders. 87 
The clinical trial was approved by the Committee for Animal Experimentation, Canton of 88 
Berne, Switzerland (approval no. BE11/14, 28 April 2014), and performed with informed 89 
owner consent. 90 
 91 
Study design 92 
The study was designed as an investigator-blinded, block-randomised, prospective clinical 93 
trial. Dogs were randomly allocated to one of two treatment groups using a block 94 
randomisation method, based on shuffle and drawing of treatment assignments inside an 95 
opaque, sealed envelope. One operator not involved in the study was in charge of the 96 
allocations list, which was disclosed only at the end of the trial. 97 
 98 
A sample size calculation determined that 10 dogs were needed in each treatment group, to 99 
achieve a power of 0.9 with an α of 0.05, to detect a minimum difference of 60 min in the mean 100 
duration of analgesia (defined as the time elapsed from the spinal injection to the first 101 
administration of rescue analgesics, either intra-operative fentanyl or post-operative 102 
buprenorphine), between groups. 103 
 104 
Anaesthetic protocol and procedures 105 
After IM premedication with acepromazine (0.03 mg/kg, Prequillan, Aprovet), an 106 
appropriately sized IV catheter was placed in a cephalic vein. General anaesthesia was 107 
induced with IV propofol (Propofol, Fresenius Kabi) titrated to effect to enable orotracheal 108 
intubation, and maintained with isoflurane (IsoFlo, Abbott) vaporised in an oxygen–air 109 
mixture and delivered via a circle system. All dogs received IV lactated Ringer's solution 110 
(Ringer-Lactate, Fresenius Kabi) at a rate of 10 mL/kg/h during anaesthesia. The dorsal 111 
pedal artery of the non-surgical pelvic limb was catheterised to allow blood sampling and 112 
continuous measurement of the systolic (SAP), mean (MAP) and diastolic (DAP) arterial 113 
blood pressures. A multiparametric monitor was used to assess cardiovascular (SAP, MAP, 114 
DAP, heart rate [HR]) and respiratory (end-tidal carbon dioxide, PE′CO2; peak inspiratory 115 
pressure, PIP; respiratory rate, RR; tidal volume, TV; inspired fraction of oxygen, FIO2; end-116 
tidal isoflurane tension, PE′ISO) variables, as well as oesophageal temperature (T, °C). Data 117 
were manually recorded every 5 min until the end of anaesthesia. The dogs were allowed to 118 
breathe spontaneously unless PE′CO2 was >45 mmHg, in which case pressure-controlled 119 
ventilation with PIP set at 10 cm H2O was used to maintain PE′CO2 within the normal range. 120 
A constant PE′ISO of 1.3%, equivalent to the minimum alveolar concentration (MAC) for the 121 
species (Steffey and Mama, 2007), was targeted during anaesthesia. 122 
 123 
Hypotension, defined as MAP lower than 60 mmHg, was treated with a crystalloid bolus 124 
(10 mL/kg lactated Ringer's delivered IV over 10 min). Non-responsive hypotension was 125 
treated initially with a colloid bolus (2 mL/kg tetrastarch delivered IV over 10 min), and then 126 
with dopamine infusion, starting at a rate of 5 µg/kg/min. The dose was increased by 127 
2.5 µg/kg/min every 10 min until MAP was above 60 mmHg. 128 
 129 
Bradycardia, defined as HR lower than 45 beats per min (bpm), was treated with IV 130 
glycopyrronium, 10 µg/kg, administered as a bolus. Any clinical signs compatible 131 
with hypermagnesaemia, including cardiac bradyarrhythmias and persistent hypotension, 132 
were recorded. 133 
 134 
After tracheal extubation, carprofen (4 mg/kg) was administered IV to all dogs. Dogs were 135 
discharged from the hospital 24 h after surgery. 136 
 137 
Spinal injection 138 
Once the plane of anaesthesia was judged as adequate on the basis of clinical assessments (jaw 139 
relaxation, absence of active blinking, slight or absent palpebral reflex, immobility and 140 
physiological variables within normal ranges for the species), spinal injection was performed 141 
by one of two anaesthetists (C.A. or D.C.), who were blinded to the treatment. The dogs were 142 
positioned in lateral recumbency with the limb to be operated on in a dependent position, with 143 
both pelvic limbs pulled symmetrically cranially to maximise the length of the dorsal lumbar 144 
intervertebral spaces. The iliac wings and the dorsal spinous processes of L5, L6 and L7 were 145 
used as anatomical landmarks. After surgical preparation of the area, a 75 mm × 19 G spinal 146 
needle was inserted towards the epidural space, with the bevel facing cranially, through the 147 
interspinous ligament between L6 and L5. The stylet was then withdrawn and the needle slowly 148 
advanced until cerebrospinal fluid was observed at the hub of the needle. A ‘dry tap’ after the 149 
third attempt of needle insertion was considered an exclusion criterion. 150 
Treatment groups 151 
Group C (control) received ropivacaine (Naropin 1%, AstraZeneca), at a dose of 1 mg/kg 152 
(0.1 mL/kg). Group M (magnesium) received a mixture of magnesium sulphate (2 g/10 mL, 153 
Magnesio Solfato, Galenica Senese), at a dose of 2 mg/kg (equivalent to a volume of 154 
0.01 mL/kg), and ropivacaine at a dose of 1 mg/kg. All treatments were administered spinally. 155 
 156 
For both treatments, the solution for injection was made hypertonic immediately before the 157 
injection by adding 50% glucose (Glucose 50% BBraun, 0.002 mL/kg) to the solution. The 158 
specific gravity of the solutions, measured with a refractometer, was 1.032 and 1.035 at 25 °C 159 
for groups C and M, respectively. The solution was injected over 1 min. Doses and volumes 160 
were based on previous reports in both human and veterinary medicine (Oezalevli et al, 2005, 161 
Arcioni et al, 2007, Bilir et al, 2007, Sarotti et al, 2011). 162 
 163 
Assessment of nociception 164 
Intra-operatively, any increase in HR, MAP and/or RR of 20% above baseline values 165 
(defined as the values recorded before skin incision, after PE′ISO values of 1.3% had been 166 
recorded consecutively for 15 min) was considered indicative of nociception. When such 167 
increases were seen for at least two of these parameters, fentanyl (3 µg/kg, IV) was 168 
administered as rescue analgesia. 169 
 170 
Post-operatively, pain was assessed with a modified multifactorial pain score (Sammarco et 171 
al, 1996, Adami et al, 2012) and the Glasgow pain scale (Holton et al., 2001). Additionally, a 172 
10 cm visual analogue scale (VAS) with end points labelled ‘worst pain imaginable’ (0) and 173 
‘no pain’ (10) was used. Cut-off values to administer rescue buprenorphine (Temgesic, 174 
10 µg/kg IV) were one or more pain scores exceeding 40% of the maximum value possible 175 
(>4 for the VAS, >6 for the Sammarco pain score, and >10 for the Glasgow pain scale). 176 
Neurological function of the pelvic limbs and the degree of motor block were assessed with a 177 
modified Tarlov scale (Table 1) (Buvanendran et al., 2002). 178 
 179 
Blood sampling 180 
The assessments were performed as soon as the dogs were conscious enough to respond to 181 
stimulation (vocal call and incitement to sit or stand up) and then at 60, 120, 180, 240 and 182 
300 min thereafter. The evaluations were performed by one of two observers (C.A. and D.C.), 183 
who were blinded to the treatment. During preliminary tests, comparable pain and motor block 184 
scores were determined by the two observers when independently evaluating the same dogs. 185 
 186 
Statistical analysis 187 
Normality of data was tested with the Kolmogorov–Smirnov test and the Shapiro–Wilk test. 188 
Repeated measures ANOVA, followed by Tukey–Kramer's multiple comparison test, was used 189 
for the plasma magnesium concentrations, for physiological variables and for post-operative 190 
pain and Tarlov scores, with treatment (group) and time of data collection as factors. 191 
Physiological variables used for statistical analysis were recorded at three predefined time 192 
points: (1) before the beginning of surgical stimulation (used as baseline); (2) immediately after 193 
skin incision; and (3) immediately after the beginning of tibial osteotomy. 194 
 195 
The duration of anaesthesia and analgesia, as well as the number of intra-operative fentanyl 196 
and post-operative buprenorphine boluses received by each group, was tested using either one 197 
way ANOVA followed by a Bonferroni multiple comparison test, or Kruskal–Wallis ANOVA 198 
on ranks followed by Dunn's test. The proportion of dogs within each group showing 199 
hypotension and/or bradyarrhythmias was analysed with Fisher's exact test. 200 
 201 
Commercially available software (NCSS-2007, SigmaStat; SigmaPlot 12, Systat Software) 202 
was used. P values < 0.05 were considered statistically significant. 203 
 204 
Results 205 
Eleven female dogs (seven of which were neutered) and nine males (six of which were 206 
neutered) were enrolled in the study. The dogs weighed 35.5 ± 22.0 kg, with a mean age of 207 
12.5 ± 5.8 years. Data for age, bodyweight, intra-operative fentanyl requirement, duration of 208 
anaesthesia and analgesia and plasma magnesium concentrations were normally distributed. 209 
The number of cases per treatment group was equally distributed between the two observers. 210 
 211 
Duration of anaesthesia was 267.3 ± 36.0 min (mean ± standard deviation) in group M and 212 
282 ± 36.0 min in group C; this difference was not statistically significant (P = 0.37). Group M 213 
experienced significantly longer analgesia (527.0 ± 341.0 min; Fig. 1) and required fewer intra-214 
operative fentanyl boluses (median 0, range 0–1; Fig. 2) than group C (176.0 ± 109.0 min, 215 
P = 0.015; median 1.5, range 0–4 boluses, P = 0.0018; respectively). 216 
 217 
Intra-operative physiological variables remained within normal ranges for the species and no 218 
differences were detected between treatments or time points (Fig. 3). However, one dog in 219 
group M and one dog in group C showed moderate sinus bradycardia (40 beats per min) and 220 
arterial hypotension (MAP, 50 and 55 mmHg, respectively) shortly after the spinal injection, 221 
which responded to glycopyrronium and colloid administration, respectively. None of the dogs 222 
required rescue buprenorphine before the final pain assessment. 223 
 224 
Post-operatively, there were no significant differences between groups or time points in VAS 225 
(P = 0.36 and P = 0.57) and Sammarco (P = 0.17 and P = 0.16) pain scales (Fig. 4). However, 226 
group M had significantly lower scores for the Glasgow pain scale (P = 0.012) and the Tarlov 227 
scale (P = 0.049) compared to group C (Fig. 4). The Glasgow (P = 0.08) and the Tarlov 228 
(P <0.001) scores significantly increased over time in both groups. Two dogs in group M 229 
showed a persistent motor block, accompanied by loss of deep pain sensation, which lasted 24 230 
and 18 h; neurological function of the pelvic limbs normalised progressively and no long-term 231 
complications were observed, although these two dogs required longer hospitalisation and were 232 
discharged 72 h after surgery. 233 
 234 
Total plasma magnesium concentrations remained within physiological ranges for the species 235 
(Fig. 5) and no significant differences were observed between subjects (P = 0.015) or between 236 
time points (P = 0.61). 237 
 238 
Discussion  239 
The main finding of this study is that spinal administration of magnesium potentiates the 240 
analgesia provided by ropivacaine in dogs undergoing elective orthopaedic surgery. However, 241 
magnesium also prolongs the duration of motor block, which makes it a less attractive 242 
adjunctive analgesic for peri-operative pain in client-owned dogs, especially in those 243 
undergoing TPLO, as they are frequently large breed dogs. Persistent motor block is likely to 244 
cause discomfort and to increase the costs of hospitalisation. This is in contrast with the 245 
findings of most reports focusing on the neuroaxial use of magnesium in both humans and 246 
canine patients, which indicated a lack of effect of magnesium on motor function when 247 
administered by either epidural or spinal routes (Buvanendran et al, 2002, Yousef, Amr, 2010, 248 
Shahi et al, 2014, Bahrenberg et al, 2015). Nonetheless, magnesium was found to prolong and 249 
enhance brachial plexus motor block when used with lidocaine in human patients (Haghighi et 250 
al., 2015). 251 
 252 
The mechanisms by which magnesium causes motor block are unknown. Magnesium sulphate 253 
is an inorganic salt which readily dissolves in water and becomes almost completely 254 
dissociated across a wide pH range, from the low pH of the stomach to the neutral pH of 255 
extracellular and cerebrospinal fluids1. An in vitro study on isolated mammalian dorsal root 256 
ganglion neurons showed that bivalent and trivalent metal cations transiently block voltage-257 
activated calcium channel currents (Busselberg et al., 1994). The ionised magnesium released 258 
by its salt could have acted so, blocking the calcium currents by altering the resting potential 259 
of the neuronal membrane within the spinal cord. 260 
 261 
Another possible explanation is that, because the magnesium sulphate solution used was 262 
hyperosmolar, it might have altered the osmotic homeostasis of cerebrospinal fluid and spinal 263 
cord, leading to axonal shrinking and transient neurological dysfunction. In vitro studies have 264 
shown that osmotically perturbed neurons are capable of regulating their membrane 265 
capacitance, structural organisation and topology, and that these changes are reversible (Wan 266 
et al, 1995, Mills, Morris, 1998). Furthermore, dynamic changes in neuronal volume and 267 
surface area caused by osmotic manipulation of isolated ganglia resulted in blockade of 268 
transmembrane sodium channels (Mills and Morris, 1998), which is also a well-recognised 269 
mechanism of action by which local anaesthetics interrupt sensory and motor transmission. For 270 
most solutions, however, osmolarity and specific gravity usually change in parallel, and 271 
therefore this explanation is less likely because the solution for injection in both groups had 272 
very similar specific gravity. 273 
 274 
Spinal administration of local anaesthetics has been shown to provide adequate analgesia to 275 
dogs undergoing orthopaedic procedures (Sarotti et al., 2011), and is a commonly used 276 
technique in clinical practice. For this reason, ropivacaine was selected for use in the positive 277 
control group in this trial. 278 
 279 
Spinal administration of magnesium did not increase total plasma magnesium concentrations 280 
in the dogs enrolled in this trial. However, one limitation of our methods is that plasma 281 
magnesium concentrations do not correlate with tissue concentrations, with the exception of 282 
interstitial fluid and bone, nor does it reflect total body magnesium (Elin, 2010). Moreover, 283 
only total magnesium, rather then the ionised, biologically active form of the ion, could be 284 
measured. Another limitation is that blood was collected over a relatively short period of time; 285 
more frequent sampling over a longer period, though not feasible in client-owned animals, 286 
would have provided a more complete picture of magnesium uptake and distribution. However, 287 
because clinical signs compatible with hypermagnesaemia were not observed, it is reasonable 288 
to assume that ionised magnesium stayed within acceptable ranges for the species. 289 
 290 
Although cardiovascular variables remained within physiologically acceptable limits, spinal 291 
injection in both groups resulted in a transient decrease in heart rate and arterial blood pressure. 292 
Additionally, one dog in each group experienced persistent hypotension and bradycardia, 293 
which required treatment with colloids and anticholinergics. Administration of ropivacaine by 294 
the spinal route might result in decreased sympathetic outflow to the cardiovascular system 295 
(Levin et al., 1998). However, because the incidence of cardiovascular side effects did not 296 
differ between treatments, it is unlikely that they were caused by magnesium. 297 
 298 
Conclusions 299 
The addition of magnesium sulphate to spinal ropivacaine increased the intensity and the 300 
duration of peri-operative analgesia in dogs undergoing orthopaedic surgery, but the potential 301 
for prolonged motor block could limit its utility in clinical practice. Further research might help 302 
identify a dose with similar analgesic effects but with less potential for prolonged motor block. 303 
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  387 
Figure legends: 388 
Fig. 1. Duration of analgesia (min) in dogs receiving a spinal injection of either ropivacaine 389 
alone (group C, n = 10) or a combination of ropivacaine and magnesium (group M, n = 10). 390 
The asterisk indicates a statistically significant difference between treatments (P <0.05). The 391 
lines indicate median values. The upper and lower boxes indicate the 75% and 25% of the 392 
values which fall below the upper and lower quartiles, respectively. The upper and lower 393 
whiskers indicate the maximum and minimum values. 394 
 395 
  396 
Fig. 2. Number of intra-operative fentanyl boluses (3 µg/kg each bolus) administered to 20 397 
dogs receiving a spinal injection of either ropivacaine alone (group C, n = 10) or a combination 398 
of ropivacaine and magnesium (group M, n = 10). The lines indicate median values. The upper 399 
and lower boxes indicate the 75% and 25% of the values which fall below the upper and lower 400 
quartiles, respectively. The upper and lower whiskers indicate the maximum and minimum 401 
values. The dots indicate the outliers. The asterisks indicate a statistically significant difference 402 
between treatments (P <0.05). 403 
 404 
  405 
Fig. 3. Values for heart rate (HR, beats per min [bpm]) and mean arterial pressure (MAP, 406 
expressed in mmHg) for 20 dogs receiving a spinal injection of either ropivacaine alone (group 407 
C, n = 10) or a combination of ropivacaine and magnesium (group M, n = 10). Data were 408 
recorded at three different time points: (1) before the beginning of surgical stimulation (used 409 
as baseline); (2) immediately after skin incision; and (3) immediately after the beginning of 410 
tibial osteotomy. The lines indicate median values. The upper and lower boxes indicate the 411 
75% and 25% of the values which fall below the upper and lower quartiles, respectively. The 412 
upper and lower whiskers indicate the maximum and minimum values. 413 
 414 
Fig. 4. Values for Sammarco pain score, Glasgow pain scale, Visual Analogue Scale (VAS) 415 
and Tarlov scale for 20 dogs receiving a spinal injection of either ropivacaine alone (group C, 416 
n = 10) or a combination of ropivacaine and magnesium (group M, n = 10). Data were recorded 417 
at four different time points: at recovery, as soon as the dogs were conscious enough to be 418 
examined (time point 1), and then 1, 2 and 3 h after that (time points 2, 3 and 4, respectively). 419 
The lines indicate median values. The upper and lower boxes indicate the 75% and 25% of the 420 
values which fall below the upper and lower quartiles, respectively. The upper and lower 421 
whiskers indicate the maximum and minimum values. The asterisks and the daggers indicate 422 




Fig. 5. Mean values (±standard deviations) of total plasma magnesium concentrations 427 
(mmol/L) for 20 dogs receiving a spinal injection of either ropivacaine alone (group C, n = 10) 428 
or a combination of ropivacaine and magnesium (group M, n = 10). Blood was sampled at the 429 
following time points: before spinal injection (0, baseline), and then at 15, 60, 120 and 240 min 430 
thereafter. 431 
 432 
  433 





Flaccid paraplegia, no movements of the pelvic limbs, possible loss of bowel/urinary bladder control 
Grade 
1 
Spastic paraplegia with moderate or vigorous purposeless movements of the pelvic limbs. No sitting, 
unable to walk 
Grade 
2 
Good movements of the pelvic limbs but unable to stand 
Grade 
3 




Able to stand and walk normally, some muscle weakness of the pelvic limbs may be seen 
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